BiologybioRxiv
Heuristic editor, no API keyVerdict: NotableA unified framework for quantitative splicing and transcript prediction
RNA splicing is frequently disrupted by genetic variation, contributing to a wide range of human diseases.
Key numbers
- 15% of the excess genetic
Caveats
- Not randomized: its findings are associations.
- Preprint; not yet peer reviewed.
VerdictWorth a reader's time today.
Abstract
RNA splicing is frequently disrupted by genetic variation, contributing to a wide range of human diseases. Identifying the variants responsible for altered splicing is therefore crucial but has long been challenging. Deep learning models that predict splicing from genomic sequence have substantially advanced their detection, but accurately resolving their quantitative effects on splicing and the resulting transcripts remains an unmet need. Here we introduce SpliceAI2, a deep learning model trained end-to-end on splice site, splice junction, and transcript usage across multiple mammalian species. SpliceAI2 reconstructs complete transcripts directly from genomic sequence and considerably improves identification of splice-altering variants and quantification of their effects in diverse benchmarks spanning cryptic splicing, splicing quantitative trait loci, and massively parallel reporter assays. Human population datasets provide independent validation of these predicted functional effects through evidence of natural selection and associated changes in plasma protein abundance. Application to a rare disease cohort reveals that predicted splice-altering variants are highly enriched in disease-associated genes and account for 15% of the excess genetic burden, with approximately half residing in deep intronic regions likely missed by exome sequencing. Together, these findings establish SpliceAI2 as a major step forward in interpreting splice-altering variants across the human genome.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ████░ 4 | 24% | A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing). |
| Magnitude | ██░░░ 2 | 16% | Solid incremental gain on a meaningful problem. |
| Evidence | ███░░ 3 | 20% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ██░░░ 2 | 20% | A new combination of known ideas. |
| Trajectory | ███░░ 3 | 10% | A clear path to scale. |
| Stakes | ██░░░ 2 | 10% | Benefits a professional community (practitioners, clinicians, engineers). |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we propose, new method); breadth (wide range, many tasks); verification (multiple benchmarks, independent replication). Red flags: not randomized.
How the score was computed
- Merit
- 5.6 / 10
- Adjusted merit
- 4.7 / 10
- Attention
- 0%
- Freshness
- 88%